Global LFA-based Cardiac Marker Market Growth (Status and Outlook) 2025-2031

The global LFA-based Cardiac Marker market size is predicted to grow from US$ 3880 million in 2025 to US$ 5807 million in 2031; it is expected to grow at a CAGR of 7.0% from 2025 to 2031.

LFA-based Cardiac Marker is a cardiac marker test based on lateral flow chromatography technology. Lateral flow chromatography technology is a detection method based on the principle of paper chromatography. It is widely used in the detection of disease biomarkers, especially in line with the World Health Organization's REASSURED principle in clinical testing, that is, reasonable cost, high sensitivity, strong specificity, convenient operation, fast and stable, no need for special equipment, easy promotion, real-time feedback, easy sampling, and environmentally friendly. Cardiac markers refer to proteins or enzymes that are released into the peripheral blood and detected during the course of heart disease. They can reflect changes in the structure or function of the heart. Cardiac marker detection based on lateral flow chromatography technology uses the advantages of lateral flow chromatography technology to quickly, accurately and conveniently detect cardiac markers to meet the clinical needs for immediate detection of heart disease.

Market Drivers

Rising Prevalence of Cardiovascular Diseases:

The prevalence of cardiovascular diseases is increasing globally, especially in low- and middle-income countries. This has led to an increase in demand for cardiac marker testing, as cardiac marker testing plays an important role in early diagnosis, risk assessment, and treatment monitoring of heart disease.

Technological Advances and Cost Reductions:

With the advancement of science and technology, the sensitivity and specificity of lateral flow chromatography technology has continued to improve, while the cost of testing has gradually decreased. This has made cardiac marker testing based on lateral flow chromatography technology more popular and acceptable, further driving the development of the market.

Growing Demand for Home Testing:

Home testing (also known as self-testing) allows users to test self-collected samples and obtain results without the assistance of trained medical professionals. This testing method plays an important role in cardiovascular diseases and infectious diseases. With the improvement of consumers' health awareness and the popularity of home testing products, the demand for cardiac marker home testing products based on lateral flow chromatography technology is also increasing.

Support from policies and regulations:

The policy support of governments for medical health and technological innovation has provided a good policy environment for the development of the cardiac marker testing market based on lateral flow chromatography technology. For example, the government may introduce relevant policies to encourage innovation, reduce testing costs, and improve testing accuracy, thereby promoting the development of the market.

Population aging and increased medical needs:

As the global population ages, the elderly population's demand for medical and health services continues to increase. Heart disease is one of the common chronic diseases among the elderly, so the application prospects of cardiac marker detection based on lateral flow chromatography technology in the elderly population are broad.

In summary, the development of the cardiac marker detection market based on lateral flow chromatography technology is driven by a variety of factors, including the increase in the prevalence of cardiovascular diseases, technological advances and cost reductions, the growth of home testing needs, policy and regulatory support, and the aging population and increased medical needs. These factors have jointly promoted the rapid development and widespread application of the market.

LPI (LP Information)' newest research report, the “LFA-based Cardiac Marker Industry Forecast” looks at past sales and reviews total world LFA-based Cardiac Marker sales in 2024, providing a comprehensive analysis by region and market sector of projected LFA-based Cardiac Marker sales for 2025 through 2031. With LFA-based Cardiac Marker sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world LFA-based Cardiac Marker industry.

This Insight Report provides a comprehensive analysis of the global LFA-based Cardiac Marker landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on LFA-based Cardiac Marker portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global LFA-based Cardiac Marker market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for LFA-based Cardiac Marker and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global LFA-based Cardiac Marker.

This report presents a comprehensive overview, market shares, and growth opportunities of LFA-based Cardiac Marker market by product type, application, key players and key regions and countries.

Segmentation by Type:
Troponin
CK-MB
Myoglobin
Others

Segmentation by Application:
Laboratory Testing
Point-of-care Testing

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Abbott
Siemens
Danaher
Bio-Rad Laboratories
BioMérieux
Thermo Fisher
Ortho Clinical Diagnostics
LSI Medience Corporation
Randox laboratories
Wondfo Biotech

Please note: The report will take approximately 2 business days to prepare and deliver.